Japanese drugmaker Takeda recently announced refunds to 340B covered entities for 28 drugs, including one of its top-selling attention-deficit medications. [...] …
Month: April 2024
SPONSORED CONTENT
TIP: When negotiating Single Case Agreements (SCA), it’s important to include payment terms. An SCA without terms can lead to lengthy delays in
The 340B drug discount program—and congressional activity associated with it—remained a hot topic for lobbyists in the first three months [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Following the recent death of former Arkansas governor and U.S. Sen. David Pryor, he is being remembered for his important [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Attorneys for both covered entities and drug manufacturers say they expect a significant number of filings to the newly re-established [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A drug industry vendor and a conservative non-profit each urged a full federal appeals court to rehear a case on [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The state agency tasked with implementing Maine’s state 340B hospital reporting requirement has proposed a rule with additional data and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Thousands of covered entities that purchased more than one hundred Novartis products between late 2019 and early 2023 will be [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
After over 30 years of working in Washington, D.C., I have become accustomed to the expression “politics ain’t beanbag.” The [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Provider advocates celebrated—with some reservations—the recently issued final rule reshaping the Administrative Dispute Resolution (ADR) process for 340B stakeholders. On [...] …
